P172 - Post-chemotherapy residual mass resection in testicular cancer
Publication date: November 2018Source: European Urology Supplements, Volume 17, Issue 14Author(s): J.M. Blok, R. Meijer, A. Bex, H. Van Der Poel, R. Bosch, S. Horenblas
Authors: Fung C, Dinh PC, Fossa SD, Travis LB Abstract Testicular cancer (TC) is the most common cancer among men aged 18 to 39 years. It is highly curable, with a 10-year relative survival approaching 95% due to effective cisplatin-based chemotherapy. Given the increasing incidence of TC and improved survival, TC survivors (TCS) now account for approximately 4% of all US male cancer survivors. They have also become a valuable cohort for adult-onset cancer survivorship research, given their prolonged survival. Commensurately, long-term treatment-related complications have emerged as important survivorship issues. T...
Conditions: Testicular Cancer; Colorectal Neoplasms Intervention: Diagnostic Test: Colonoscopy surveillance Sponsor: The Netherlands Cancer Institute Not yet recruiting
by Jennifer S. Walsh, Helen Marshall, Isabelle L. Smith, Diana M. Greenfield, Jayne Swain, Emma Best, James Ashton, Julia M. Brown, Robert Huddart, Robert E. Coleman, John A. Snowden, Richard J. Ross BackgroundYoung male cancer survivors have lower testosterone levels, higher fat mass, and worse quality of life (QoL) than age-matched healthy controls. Low testosterone in cancer survivors can be due to orchidectomy or effects of chemotherapy and radiotherapy. We have undertaken a double-blind, placebo-controlled, 6-month trial of testosterone replacement in young male cancer survivors with borderline low testosterone (7 &nd...
Series Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensA greater understanding of the hypersensitivity and curability of testicular germ cell tumors (TGCTs) has the potential to inform strategies to sensitize other solid tumors to conventional chemotherapies. More than 80% of metastatic TGCT patients are cured with cisplatin-based chemotherapy. However, resistance can occur, which results in poor outcomes. The mechanisms of cisplatin hypersensitivity and resistance in these tumors and embryonal carcinoma (EC), the stem cells of TGCTs, remain largely undefined. To study the mechanisms of cisp...
Abstract OBJECTIVES: Primary tumor size (PTS) is the main prognostic factor for relapse in clinical stage (CS) IA testicular seminoma (T1N0M0S0) and the 8th edition of the Tumor-Node-Metastasis staging system now subcategorizes pT1 tumors into pT1a and pT1b based on PTS (
CONCLUSIONS: A rigorous use of classifications is mandatory to define staging since initial diagnosis. Applying treatments based on these classifications leads to excellent survival rates (99 % in CSI, 85 % in CSII+). PMID: 31610870 [PubMed - in process]
Condition: Testicular Cancer Interventions: Diagnostic Test: Skin biopsy; Diagnostic Test: Subcutaneous fat biopsy Sponsors: University Medical Center Groningen; Dutch Cancer Society Recruiting